Biote provides preliminary 2023 results and initial 2024 guidance

Irving, texas--(business wire)--biote corp. (nasdaq: btmd) (“biote” or the “company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and adjusted ebitda to be slightly below prior guidance. the company had previously forecast that revenue and adjusted ebitda would be toward the lower end of the previously announced ranges of $190-$200 million and $56-.
BTMD Ratings Summary
BTMD Quant Ranking